ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dezandrodeg

Also written as “BMS-986365” and “CC-94676”.

Its studies are mostly in Prostatic Neoplasms, led by Bristol-Myers Squibb.

Drug pageDezandrodeg: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 17, 20245 company-led studies, 1 open or runningNext primary completion: Sep 12, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb51 open or runningphase 3since Dec 17, 2024May 29, 2020Sep 12, 2027phase 3 · NCT06764485

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 29, 2020First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04428788 · 131 enrolled · United States
  2. May 13, 20242 phase 1 studiesNCT06417229, NCT06433505
  3. Dec 17, 2024Phase 3 study in Prostatic NeoplasmsNCT06764485 · 960 enrolled · United States, Argentina, Australia and more
  4. Nov 17, 2025Phase 1 study in Healthy VolunteersNCT07242781 · 22 enrolled · United States
  5. Jan 29, 2026Named dezandrodegINNProposed as its International Nonproprietary Name in WHO's List 134 · before, BMS-986365, CC-94676

Ahead

  1. Sep 12, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06764485

TargetBeta

AR →read by rule
“An orally bioavailable androgen receptor (AR) degrader, ”NCIt, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07242781Healthy Volunteers · United States1TerminatedApr 9, 202622
NCT06764485Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingSep 12, 2027960
NCT06433505Healthy Volunteers · United States1CompletedFeb 14, 202524
NCT06417229Healthy Participants · United States1CompletedFeb 19, 2025102
NCT04428788Prostatic Neoplasms · United States1CompletedOct 28, 2025131

How it is read

Names in the registry

  • “BMS-986365”, 4 entries
  • “CC-94676”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.